1.18%

Gold vs US Dollar

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Cytrx Corp. (MM) (CYTR)
Cytrx Corp. (MM) (CYTR) News

CYTR Cytrx Corp. (MM)

0.31

0.00 (0.00%)

Pre Market

Last Updated: 01:00:00

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Cytrx Corp. (MM)	NASDAQ:CYTR	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.31	0.30	0.3001				0	01:00:00

EDISON EQUITY RESEARCH - CYTRX

31/03/2015 5:14pm

InvestorsHub NewsWire

EDISON EQUITY RESEARCH: CYTRX - PREPARING TO GO SOLO IN THE US ON ALDOXORUBICIN

Derma Sciences delivered a robust Q414 with rebounding sales growth but slowing cost growth. Based on lower overhead and R&D costs, we have tempered our forecast losses 2015-16e and our DCF-based valuation has been raised from $312m to $320m. Accelerated recruitment in the ongoing diabetic foot ulcer trials (DSC127) and improved cost absorption in Advanced Wound Care may lead to profitability as of 2018.

Derma Sciences is a specialty medical device/pharmaceutical company. It focuses on developing and commercialising traditional and novel advanced wound care products, including MEDIHONEY and TCC-EZ, among other brands, and DSC127, a novel pharmaceutical agent for wound healing. It is headquartered in Princeton, New Jersey, US.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports